GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (NAS:IDYA) » Definitions » Asset Turnover

IDEAYA Biosciences (IDEAYA Biosciences) Asset Turnover : 0.01 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. IDEAYA Biosciences's Revenue for the three months ended in Dec. 2023 was $3.92 Mil. IDEAYA Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $591.13 Mil. Therefore, IDEAYA Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. IDEAYA Biosciences's annualized ROE % for the quarter that ended in Dec. 2023 was -24.06%. It is also linked to ROA % through Du Pont Formula. IDEAYA Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 was -22.98%.


IDEAYA Biosciences Asset Turnover Historical Data

The historical data trend for IDEAYA Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Asset Turnover Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - 0.10 0.08 0.13 0.05

IDEAYA Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.01 0.02 0.01

Competitive Comparison of IDEAYA Biosciences's Asset Turnover

For the Biotechnology subindustry, IDEAYA Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEAYA Biosciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Asset Turnover falls into.



IDEAYA Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

IDEAYA Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=23.385/( (387.969+649.316)/ 2 )
=23.385/518.6425
=0.05

IDEAYA Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=3.922/( (532.942+649.316)/ 2 )
=3.922/591.129
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


IDEAYA Biosciences  (NAS:IDYA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

IDEAYA Biosciences's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-135.82/564.5695
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-135.82 / 15.688)*(15.688 / 591.129)*(591.129/ 564.5695)
=Net Margin %*Asset Turnover*Equity Multiplier
=-865.76 %*0.0265*1.047
=ROA %*Equity Multiplier
=-22.98 %*1.047
=-24.06 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

IDEAYA Biosciences's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-135.82/591.129
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-135.82 / 15.688)*(15.688 / 591.129)
=Net Margin %*Asset Turnover
=-865.76 %*0.0265
=-22.98 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


IDEAYA Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEAYA Biosciences (IDEAYA Biosciences) Business Description

Traded in Other Exchanges
Address
7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Executives
Yujiro S Hata director, officer: President and CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Briseno Andres Ruiz officer: See Remarks C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Jason Throne officer: VP, General Counsel C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Paul A. Stone officer: SVP, General Counsel C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Darrin Beaupre officer: SVP, Chief Medical Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael Anthony White officer: SVP, Chief Scientific Officer C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Michael P. Dillon officer: SVP, Chief Scientific Officer C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Mark Lackner officer: SVP, Head of Biology C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Andrew J. Schwab 10 percent owner, Former 10% holder C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman 10 percent owner, Former 10% holder C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Scott M Rocklage 10 percent owner, Former 10% holder C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Iv, L.p. 10 percent owner, Former 10% holder 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107